SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Golden Lee Scott

(Last)

(First)

(Middle)

C/O PTC THERAPEUTICS, INC.

(Street)

SOUTH PLAINFIELD

07066

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/06/2023

3. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	39,286⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽²⁾	05/10/2030	Common Stock	40,500	$47.06	D
Stock Option (Right to Buy)	⁽³⁾	01/05/2031	Common Stock	23,100	$66.49	D
Stock Option (Right to Buy)	⁽⁴⁾	01/06/2032	Common Stock	10,000	$38.1	D
Stock Option (Right to Buy)	⁽⁴⁾	01/06/2032	Common Stock	13,590	$38.1	D
Stock Option (Right to Buy)	⁽⁵⁾	01/04/2033	Common Stock	11,400	$39.42	D
Stock Option (Right to Buy)	⁽⁶⁾	04/23/2033	Common Stock	21,000	$52.85	D

Explanation of Responses:

1. Includes: 1) 713 unvested Restricted Stock Units ("RSUs") from an award of 2,850 RSUs granted on May 11, 2020, which vests in four equal annual installments over four years, commencing on May 11, 2021; 2) 1,980 unvested RSUs from an award of 3,960 RSUs granted on January 6, 2021, which vests in four equal annual installments over four years, commencing on January 6, 2022; 3) 6,117 unvested RSUs from an award of 8,155 RSUs granted on January 7, 2022, which vests in four equal annual installments over four years, commencing on January 7, 2023; 4) 4,500 unvested RSUs from an award of 6,000 RSUs granted on January 7, 2022, which vests in four equal annual installments over four years, commencing on January 7, 2023; 5) 10,640 RSUs granted on January 5, 2023, which vest in four equal annual installments over four years, commencing on January 5, 2024; and 6) 8,400 RSUs granted on April 24, 2023, which vest in four equal annual installments over four years, commencing on April 24, 2024

2. This option was granted on May 11, 2020, and vests over four years, with 25% of the shares underlying the option vesting on May 11, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on August 11, 2021.

3. This option was granted on January 6, 2021, and vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022.

4. This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.

5. This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.

6. This option was granted on April 24, 2023, and vests over four years, with 25% of the shares underlying the option vesting on April 24, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on July 24, 2024.

	/s/ Avraham S. Adler, Attorney-in-Fact	06/13/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.